Shots:

• The study evaluates the LUNAR-2 test in 699 patients with early-stage Stage 1- 2- or 3 CRC which showed a 96% overall sensitivity & 94% specificity. The test is designed to detect early-stage cancer in screen-eligible asymptomatic adults through a blood sample
• In an additional analysis- the test showed 93% overall sensitivity in patients with Stage 1 & 2 CRC while 90% of patients with asymptomatic Stage 1 or 2 CRC
• The test is being evaluated in an ongoing ECLIPSE trial in 10000+ patients for the same indication & the trial is expected to complete enrollment in 2021. If successful- results will be submitted to the US FDA as part of Guardant’s application for the approval of Lunar-2

 ­ | Ref: Businesswire | Image: Businesswire